Hum. Reprod. Advance Access first published online on February 23, 2006
This version published online on March 3, 2006
Human Reproduction, doi:10.1093/humrep/del003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Endocrine Section, First Department of Internal Medicine, Laiko General Hospital, Medical School, University of Athens, Athens, Greece
* To whom correspondence should be addressed. BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance (IR) and related disorders. Elevated serum levels of cellular adhesion molecules (CAMs) reflect low-grade chronic inflammation and have been associated with several insulin-resistant states. The objective of this study is to investigate whether soluble inflammatory markers [soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leu-kocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP)] are altered in PCOS and to further elucidate the effect of metformin treatment on their levels. METHODS: Two young populations were studied [62 women with PCOS and 45 normal women of similar age, BMI and waist-to-hip ratio (WHR)]. Plasma levels of sICAM-1, sVCAM-1, sE-selectin and high-sensitivity CRP (hsCRP) were measured in both groups. Additionally, the effect of metformin on these molecules was investigated in 22 women with PCOS who accepted to metformin protocol (1700 mg daily for a 6-month period). RESULTS: In the total population studied, plasma levels of hsCRP (mg/l), sICAM-1 (ng/ml) and sE-selectin (ng/ml) were higher in the PCOS group compared with those in controls (hsCRP 1.31 ± 0.22 versus 0.92 ± 0.27, P = 0.014, sICAM-1 301.21 ± 24.80 versus 209.86 ± 17.05, P = 0.025, sE-selectin 57.37 ± 4.08 versus 45.67 ± 4.62, P = 0.045, respectively). sVCAM-1 (ng/ml) did not differ statistically among the two groups (P = 0.896). A significant reduction in hsCRP and sVCAM-1 was achieved after 6 months of metformin administration: PCOS pretreatment hsCRP 1.92 ± 0.60 versus PCOS post-treatment hsCRP 0.52 ± 0.26, P = 0.005; PCOS pretreatment sVCAM-1 668.09 ± 98.38 versus PCOS post-treatment sVCAM-1 365.82 ± 99.77, P = 0.039. CONCLUSION: These findings imply the presence of chronic inflammation in women with PCOS. Metformin decreases the levels of plasma inflammatory indices. Further investigation is required to determine whether these findings may prove to be of clinical significance for PCOS patients.
Received September 9, 2005
Revised December 12, 2005
Accepted December 20, 2005
Article
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Evanthia Diamanti-Kandarakis 1 *,
Thomas Paterakis 1,
Krystallenia Alexandraki 1,
Christina Piperi 2,
Athanasios Aessopos 1,
Ilias Katsikis 3,
Nikolaos Katsilambros 4,
George Kreatsas 5,
and
Dimitrios Panidis 3
2 Laboratory of Biological Chemistry, Medical School, University of Athens, Athens, Greece
3 Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki
4 Department of Propedeutic Medicine, Laiko General Hospital, Medical School, University of Athens, Athens, Greece
5 Department of Obstetrics and Gynaecology, Aretaieion Hospital Athens, Medical School, University of Athens, Athens, Greece
Evanthia Diamanti-Kandarakis, E-mail: akandara{at}otenet.gr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur. J. Endocrinol., April 1, 2008; 158(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sattar and S. M. Nelson Polycystic Ovarian Syndrome, Biomarkers, and Metformin: Research, Risk, and Reality J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 34 - 36. [Full Text] [PDF]
|
|
|
|
|
|
D. Heutling, H. Schulz, I. Nickel, J. Kleinstein, P. Kaltwasser, S. Westphal, F. Mittermayer, M. Wolzt, K. Krzyzanowska, H. Randeva, et al. Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio, F. Manguso, S. Di Biase, A. Falbo, F. Giallauria, D. Labella, A. Tolino, G. Lombardi, A. Colao, and S. Palomba Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study Eur. J. Endocrinol., July 1, 2007; 157(1): 69 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Banaszewska, L. Pawelczyk, R. Z. Spaczynski, J. Dziura, and A. J. Duleba Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 456 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. DIAMANTI-KANDARAKIS, T. PATERAKIS, and H. A. KANDARAKIS Indices of Low-Grade Inflammation in Polycystic Ovary Syndrome Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 175 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Elia, V. Sander, C.G. Luchetti, M.E. Solano, G. Di Girolamo, C. Gonzalez, and A.B. Motta The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice Mol. Hum. Reprod., August 1, 2006; 12(8): 475 - 481. [Abstract] [Full Text] [PDF]
|
|